Redmile Group’s Heron Therapeutics HRTX Stock Holding History

Redmile Group’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-10,850	Closed	-$343K	–	84
2018 Q3	$343K	Buy	+10,850	New	+$404K	0.01%	74

Other funds holding HRTX

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Redmile Group's HRTX Position: Q4 2018 in Review

Redmile Group sold out of Heron Therapeutics (HRTX) in Q4 2018, closing a stake of 10,850 shares — an estimated $343K sold.

Redmile Group first reported a position in HRTX in Q3 2018 and held it in 1 quarter. The position peaked at $343K in Q3 2018. 176 funds tracked by Wall St. Rank hold HRTX as of Q4 2018.

Redmile Group reported no remaining Heron Therapeutics position as of Q4 2018 after selling out during the quarter.
Redmile Group sold 10,850 Heron Therapeutics shares in Q4 2018, an estimated $343K.
Redmile Group first reported a position in Heron Therapeutics in Q3 2018 and held it in 1 quarter.
Redmile Group's Heron Therapeutics position peaked at $343K in Q3 2018.
176 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2018.

Based on Redmile Group's 13F filing for Q4 2018, filed 14 Feb 2019.